Evidence map›Paper›PMID 39704263›Full record

ArticleOncology reports2025

Tomohiro Miyamoto, Naomasa Fukase, Teruya Kawamoto, Shuichi Fujiwara, Hitomi Hara, Ryoko Sawada, Yuta Nakamatsu, Yutaka Mifune, Kenichiro Kakutani, Yuichi Hoshino and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tomohiro MiyamotoDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Naomasa FukaseDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Teruya KawamotoDepartment of Orthopaedic Surgery, Konan Medical Center, 658‑0064 Kobe, Japan.
Shuichi FujiwaraDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Hitomi HaraDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Ryoko SawadaDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Yuta NakamatsuDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Yutaka MifuneDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Kenichiro KakutaniDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Yuichi HoshinoDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Shinya HayashiDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Tomoyuki MatsumotoDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Takehiko MatsushitaDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Michiyo Koyanagi-AoiDivision of Stem Cell Medicine, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Takashi AoiDivision of Stem Cell Medicine, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Toshiyuki TakemoriDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Shunsuke YahiroDepartment of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673‑8558, Japan.
Ryosuke KurodaDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.
Toshihiro AkisueDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650‑0017, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) have been implicated as critical mediators in the progression, chemoresistance and metastatic capabilities of diverse malignancies, including osteosarcoma (OS). The authors have succeeded in generating CSC‑like cells (MG‑OKS) from the OS cell line MG‑63 by transducing defined factors. A significant increase in small proline‑rich protein 1A (SPRR1A) expression, a cross‑linked envelope protein in keratinocytes, was observed in MG‑OKS cells. Therefore, SPRR1A could be involved in tumor initiation, growth and poor OS progression. However, its specific role in OS remains unclear. The present study aimed to evaluate the role of SPRR1A in OS both

Indexed as

Bone NeoplasmsCell MovementCell ProliferationCornified Envelope Proline-Rich ProteinsNeoplastic Stem CellsOsteosarcomaAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMice, NudeRNA, Small InterferingXenograft Model Antitumor AssaysCornified Envelope Proline-Rich ProteinsRNA, Small InterferingCSCfocal adhesionOSSPRR1Atumor progression

Identifiers

PMID39704263
PMCPMC11667212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.